Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 601–700 of 1,000
Maaswinkel, H., Mason, B., & Li, L. (2003) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2003.08.004 · Cited by 25
Kurosaki, T., Uematsu, M., Shimoda, K., Suzuma, K., Nakai, M., Nakamura, T., Kitahara, T., Kitaoka, T., & Sasaki, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00728 · Cited by 23
Rossi, C., Strettoi, E., & Galli‐Resta, L. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09924.2003 · Cited by 25
“Promising attempts are in progress to prevent photoreceptor loss or restore functional photoreceptors in this family of diseases (Frasson et al., 1999; Acland et al., 2001; Lund et al., 2001).”
BackgroundAdeno-associated virus serotype-9 efficiently transduces the retinal outer plexiform layer.
Lei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · PubMed Central · Cited by 27
Effects of Subretinal Electrical Stimulation in Mer-KO Mice
Mocko, J. A., Kim, M., Faulkner, A. E., Cao, Y., Ciavatta, V. T., & Pardue, M. T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6750 · Cited by 25
In vivo Gene Transfer to Healthy and Diabetic Canine Pancreas
Ayuso, E., Chillón, M., García, F., Agudo, J., Andaluz, A., Carretero, A., Monfar, M., Moya, M., Montané, J., Otaegui, P. J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.017 · Cited by 30
Ex Vivo Gene Therapy and Vision
Gregory-Evans, K., Bashar, E., & Tan, M. (2012) · Current Gene Therapy · doi:10.2174/156652312800099607 · Cited by 24
Animals Models of Inherited Retinal Disease
Moshiri, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000368 · Cited by 27
Patel, C. A., Pande, S. V., Sagathia, V., Ranch, K. M., Beladiya, J., Boddu, S. H. S., Jacob, S., Al-Tabakha, M. M., Hassan, N. A. G. M., & Shahwan, M. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030837 · Cited by 27
“Additionally, even with a normal IOP, RGC degeneration advances in patients with normal tension glaucoma [66,67].”
BackgroundCommunicating the Promise for Ocular Gene Therapies: Challenges and Recommendations
Benjaminy, S., Kowal, S. P., MacDonald, I. M., & Bubela, T. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.05.026 · Cited by 27
Gene therapy: light is finally in the tunnel
Cao, H., Molday, R. S., & Hu, J. (2011) · Protein & Cell · doi:10.1007/s13238-011-1126-y · Cited by 26
“Preclinical studies with AAV2 vector demonstrated restoration of vision upon RPE65 gene transfer into RPE cells in mice and dogs (Acland et al., 2001; Li et al., 2011).”
BackgroundHasegawa, T., Ikeda, H. O., Nakano, N., Muraoka, Y., Tsuruyama, T., Okamoto‐Furuta, K., Kohda, H., & Yoshimura, N. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-015-0422-0 · Cited by 24
Concepts and Strategies in Retinal Gene Therapy
Aguirre, G. D. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22978 · Cited by 25
“Gene therapy as a therapeutic modality for treating previously incurable forms of retinal blindness is making great advances since the successful proof-of-concept studies of canine RPE65LCA in 2001.(3) The field is still young, but the excitement in both the scientific community and patient advocacy groups has been en…”
InfluentialSelf-citationScreening of theRPE65Gene in the Asian Indian Patients with Leber Congenital Amaurosis
Mamatha, G., Sundaramurthy, S., Meenakshi, S., & Kumaramanickavel, G. (2008) · Ophthalmic Genetics · doi:10.1080/13816810802008259 · Cited by 26
Gene therapy for retinal and choroidal diseases
Campochiaro, P. A. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.5.537 · Cited by 23
“Subretinal injection of AAV vectors encoding RPE65 in RPE65-/Briard dogs, resulted in ERG and behavioural evidence of vision restoration [57].”
BackgroundBeyond the injection: delivery systems reshaping retinal disease management
Rowe, L. W., Akotoye, C., Harris, A., & Ciulla, T. A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2496424 · Cited by 26
“…of the subretinal space in delivering gene therapy via the preferred adeno-associated viruses (AAVs) [104,105], including the use of an AAV2 vector to carry a wild-type RPE65 gene that demonstrated the ability to effectively rehabilitate the retinal function in a canine model of LCA [106].”
Exploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties
Gao, G., Li, Z., & Danos, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_4 · Cited by 28
Zheng, Q., Ren, Y., Tzekov, R. T., Zhang, Y., Chen, B., Hou, J., Zhao, C., Zhu, J., Zhang, Y., Dai, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044855 · Cited by 25
“More importantly, several groups have reported rescue of vision after rAAV-vector-mediated gene replacement in the Swedish Briard dog, a spontaneous RPE65-null model [14–17],”
BackgroundWolsley, C. J., Silvestri, G., O'Neill, J., Saunders, K. J., & Anderson, R. S. (2008) · Eye · doi:10.1038/eye.2008.318 · Cited by 22
The function of dog models in developing gene therapy strategies for human health
Nowend, K. L., Starr-Moss, A. N., & Murphy, K. E. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9348-0 · Cited by 25
“However, both canine and human mutations result in a complete loss of RPE65, and the briard is a canine model of LCA2 (Acland et al. 2001).”
BackgroundMethodWojno, A. P., Pierce, E. A., & Bennett, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005798 · Cited by 24
Self-citationMaurya, S., & Jayandharan, G. R. (2020) · Virus Research · doi:10.1016/j.virusres.2020.197966 · Cited by 23
Thumann, G., Stöcker, M., Maltusch, C., Salz, A. K., Barth, S., Walter, P., & Johnen, S. (2009) · Gene Therapy · doi:10.1038/gt.2009.124 · Cited by 29
Retinal Remodeling: Concerns, Emerging Remedies and Future Prospects
Krishnamoorthy, V., Cherukuri, P., Poria, D., Goel, M., Dagar, S., & Dhingra, N. K. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00038 · Cited by 24
“Devices of both types have been approved for human use and provide measurable visual acuity and rudimentary object localization/recognition (Ahuja et al., 2011; Zrenner et al., 2011; Humayun et al., 2012; da Cruz et al., 2013; Kotecha et al., 2014; Ho et al., 2015; Stingl et al., 2015).”
BackgroundBok, D. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.2.160 · Cited by 22
“Mutations were quickly discovered in the dog ortholog of RPE65(16); dogs were thereafter successfully treated for their disease with replacement gene therapy.(17) In a remarkably rapid application of these discoveries to human disease, patients with Leber congenital amaurosis due to RPE65 mutations will be enrolled in…”
BackgroundGenetic Ophthalmology and the Era of Clinical Care
Sieving, P. A., & Collins, F. S. (2007) · JAMA · doi:10.1001/jama.297.7.733 · Cited by 22
Fraefel, C., Mendes-Madeira, A., Mabon, O., Lefebvre, A., Meur, G. L., Ackermann, M., Moullier, P., & Rolling, F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302553 · Cited by 23
Comparative clinical science: The medicine of the future
Michell, A. R. (2005) · The Veterinary Journal · doi:10.1016/j.tvjl.2004.06.004 · Cited by 23
Baum, L., Chan, W. M., Li, W. Y., Lam, D. S. C., Wang, P. B., & Pang, C. P. (2003) · Ophthalmologica · doi:10.1159/000068553 · Cited by 24
Rapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium
Paskowitz, D. M., Greenberg, K. P., Yasumura, D., Grimm, D., Yang, H., Duncan, J. L., Kay, M. A., LaVail, M. M., Flannery, J. G., & Vollrath, D. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.065 · Cited by 24
Guanylate Cyclase-Activating Proteins and Retina Disease
Baehr, W., & Palczewski, K. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_4 · Cited by 25
“Viral gene transfer therapies of retinal diseases by an adeno-associated virus (AAV) vector have been very successful in several recessive animal models ( Acland et al., 2001; Bennett et al., 1999; Bennett et al., 1998; Batten et al., 2005; LaVail et al., 2000; Haire et al., 2006; Williams et al., 2006).”
BackgroundLin, C., Gould, D. J., Petersen‐Jones, S. M., & Sargan, D. R. (2002) · Journal of Small Animal Practice · doi:10.1111/j.1748-5827.2002.tb00008.x · Cited by 22
Seeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“Gene therapy for RPE65 using AAVs has been shown to restore vision in a canine model of LCA [159].”
BackgroundHernández, M., Pearce-Kelling, S. E., Rodriguez, F. D., Aguirre, G. D., & Vecino, E. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5213 · Cited by 25
“tion of retinal function after transfer of the normal cDNA to the RPE.(11,14,29) In both species, rescue of retinal function has been accompanied by restoration of some aspects of visual cortical activity measured noninvasively.”
BackgroundInfluentialSelf-citationEzra-Elia, R., Banin, E., Honig, H., Rosov, A., Obolensky, A., Averbukh, E., Hauswirth, W. W., Gootwine, E., & Ofri, R. (2014) · Documenta Ophthalmologica · doi:10.1007/s10633-014-9458-6 · Cited by 21
Self-citationProspectives for Gene Therapy of Retinal Degenerations
Thumann, G. (2012) · Current Genomics · doi:10.2174/138920212801619214 · Cited by 27
“The natural occurrence of mutation in the RPE65 gene in dogs [46] and mice [47, 48] that mimics human LCA has made possible the development of gene therapy protocols for the successful treatment of these animals [49-56] as well as the application of these gene therapy protocols to the human disease.”
BackgroundGene therapy for retinal diseases
Samiy, N. (2014) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.150831 · Cited by 24
“Bennet and Maguire continued this work by using the same techniques to rescue Briard dogs with Leber’s Congenital Amaurosis (LCA).[8] LCA is a progressive autosomal recessive disease marked by loss of photoreceptors, declining visual fields and flat electroretinography (ERG) tracings.”
MethodAlbino Mice as an Animal Model for Infantile Nystagmus Syndrome
Traber, G. L., Chen, C., Huang, Y., Spoor, M., Roos, J., Frens, M. A., Straumann, D., & Grimm, C. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10137 · Cited by 25
Redmond, T. M., Weber, C. H., Poliakov, E., Yu, S., & Gentleman, S. (2007) · PubMed · Cited by 20
Adeno-associated Virus and Lentivirus Pseudotypes for Lung-directed Gene Therapy
Wilson, J. M. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-041ms · Cited by 22
“vivo gene therapy with AAV2 which have shown promise in animal models include gene transfer to the retina and skeletal muscle (22, 23 ).”
BackgroundNew frontiers of retinal therapeutic intervention: a critical analysis of novel approaches
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2066169 · Cited by 20
“Preclinical animal studies in mice and canines harbouring the RPE65 mutant showed visual rescue by subretinal injections of AAVRPE65 [53,54].”
BackgroundDatta, S., Renwick, M., Chau, V. Q., Zhang, F., Nettesheim, E. R., Lipinski, D. M., & Hulleman, J. D. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24987 · Cited by 21
Becherucci, V., Bacci, G. M., Marziali, E., Sodi, A., Bambi, F., & Caputo, R. (2023) · Biomedicines · doi:10.3390/biomedicines11102656 · Cited by 20
“…human clinical trials for gene therapy have been As a result, human clinical trials for gene therapy have been initiated, aiming to explore the potential benefits of this novel treatment approach [7–10]. initiated, aiming to explore the potential bene fi ts of this novel treatment approach [7–10].”
BackgroundOfri, R., Reilly, C. M., Maggs, D. J., Fitzgerald, P. G., Shilo‐Benjamini, Y., Good, K. L., Grahn, R. A., Splawski, D. D., & Lyons, L. A. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16585 · Cited by 23
PROGRESS TOWARD THE MAINTENANCE AND REPAIR OF DEGENERATING RETINAL CIRCUITRY
Vugler, A. (2010) · Retina · doi:10.1097/iae.0b013e3181e2a680 · Cited by 23
“Original studies in the RPE65 knockout canine model of LCA2 had demonstrated that subretinal AAV vector– mediated delivery of wild-type RPE65 could restore the expression of this protein in host RPE cells, together with an associated restoration of PLR responses and rod/cone ERG function.(148) The functional improveme…”
BackgroundChen, M., Wang, K., & Lin, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044036 · Cited by 20
“retinal function [66,67], suggesting the interventions have positive”
BackgroundRPGR and RP2: targets for the treatment of X-linked retinitis pigmentosa?
Veltel, S., & Wittinghofer, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903225016 · Cited by 21
“RPGRIP1 is a 144 kDa protein containing N-terminal coiled-coil domains, two C2 domains and a C-terminal domain that interacts with the RCC1-like domain of RPGR. Mutations in RPGRIP1 were found in patients with LCA, a rare inherited eye disease appearing in the early childhood [43].”
ResultInfluentialSevere Loss of Tritan Color Discrimination in RPE65 Associated Leber Congenital Amaurosis
Kumaran, N., Ripamonti, C., Kalitzeos, A. A., Rubin, G. S., Bainbridge, J. W., & Michaelides, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22905 · Cited by 20
Progressive Characterization of Visual Phenotype in Bardet-Biedl Syndrome Mutant Mice
Kretschmer, V., Patnaik, S. R., Kretschmer, F., Chawda, M. M., Hernández-Hernández, V., & May‐Simera, H. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25210 · Cited by 22
Ofri, R., & Narfström, K. L. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2006.08.014 · Cited by 27
“Three dogs were injected subretinally with a rAAV-RPE65 gene construct into one eye and the other eye was either not touched or injected intravitreally (Acland et al., 2001).”
BackgroundMethodCats: A Gold Mine for Ophthalmology
Narfström, K. L., Deckman, K. H., & Menotti-Raymond, M. A. (2013) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-031412-103629 · Cited by 24
Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders
Sharif, W., & Sharif, Z. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.03.24 · Cited by 25
Shen, W., Lai, C., Lai, Y. K. Y., Zhang, D., Zaknich, T., Sutanto, E. N., Constable, I. J., & Rakoczy, P. E. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.375 · Cited by 21
Current perspective on retinal remodeling: Implications for therapeutics
Pfeiffer, R. L., & Jones, B. W. (2022) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2022.1099348 · Cited by 21
Tissue engineering of retina and Bruch’s membrane: a review of cells, materials and processes
Tan, E. Y. S., Shi, P., Choo, C.-J., Laude, A., & Yeong, W. Y. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311390 · Cited by 22
Antioxidant and Biological Properties of Mesenchymal Cells Used for Therapy in Retinitis Pigmentosa
Limoli, P. G., Vingolo, E. M., Limoli, C., & Nebbioso, M. (2020) · Antioxidants · doi:10.3390/antiox9100983 · Cited by 22
“Examples of those models are Rd1 mices [27], Rd10 mices [28], P23H and S334ter Rhodopsin Transgenic Rats [29], Rd mices [30], Rds mices [31], Royal College of Surgeons rats [32], and RPE65 dog [33].”
BackgroundPupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis
Whiting, R. E. H., Narfström, K. L., Yao, G., Pearce, J. W., Coates, J. R., Castaner, L. J., & Katz, M. L. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.10.006 · Cited by 22
“Consequently, subjects with profoundly depressed ERG responses can retain significant visually mediated behavior (Acland et al. 2001; Melillo et al. 2012; Narfstrom et al. 2003a; Narfstrom et al. 2003b).”
BackgroundEvaluation of Candidate Genes in the Absence of Positional Information: A Poor Bet on a Blind Dog!
Aguirre‐Hernández, J., & Sargan, D. R. (2005) · Journal of Heredity · doi:10.1093/jhered/esi092 · Cited by 25
Using the NAFX to Measure the Effectiveness over Time of Gene Therapy in Canine LCA
Jacobs, J. B., Dell’Osso, L. F., Wang, Z. I., Acland, G. M., & Bennett, J. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3387 · Cited by 22
Self-citationProgress toward effective treatments for human photoreceptor degenerations
Stone, E. M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.03.006 · Cited by 23
Maaswinkel, H., Riesbeck, L. E., Riley, M. E., Carr, A. L., Mullin, J. P., Nakamoto, A. T., & Li, L. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.03.025 · Cited by 20
Burnight, E. R., Wiley, L. A., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017434 · Cited by 23
“Similarly, subretinal AAV-RPE65 delivery resulted in significant reversal of nystagmus and visual deficits in RPE65 mutant dogs (Acland et al. 2001, 2005; Narfström et al. 2003).”
BackgroundApolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
Lhériteau, E., Libeau, L., Mendes-Madeira, A., Deschamps, J.-Y., Weber, M., Le Meur, G., Provost, N., Guihal, C., Moullier, P., & Rolling, F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.46 · Cited by 18
Challenges in non-viral ocular gene transfer
Peeters, L., Sanders, N. N., Demeester, J., & Smedt, S. C. D. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350047 · Cited by 18
Pradhan, M. A., Hayes, I., & Vincent, A. L. (2009) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2009.02129.x · Cited by 18
Retinal degeneration in animal models with a defective visual cycle
Maeda, A., & Palczewski, K. (2013) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.01.001 · Cited by 21
“In 2001, the first gene transfer therapy was conducted with Swedish Briard dogs carrying an RPE65 mutation [37].”
BackgroundRecent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
Gene Therapy for Rare Neurological Disorders
Flotte, T. R., & Gessler, D. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2543 · Cited by 23
Colombo, L., Montesano, G., Sala, B., Patelli, F., Maltese, P. E., Abeshi, A., Bertelli, M., & Rossetti, L. M. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0817-z · Cited by 22
Nanoparticle‐motivated gene delivery for ophthalmic application
Mitra, R. N., Zheng, M., & Han, Z. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1356 · Cited by 21
Wen, S. F., Chen, Z., Nery, J., & Faha, B. (2003) · Experimental Eye Research · doi:10.1016/s0014-4835(03)00122-2 · Cited by 18
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
Self-citationCommentary: An Aye for Eye Gene Therapy
Bennett, J. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.177 · Cited by 19
Self-citationSommer, F., Brandl, F., & Göpferich, A. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-34133-0_27 · Cited by 17
Visual function testing: A quantifiable visually guided behavior in mice
Thompson, S., Philp, A. R., & Stone, E. M. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.020 · Cited by 17
Maier, P., Veldwijk, M. R., & Wenz, F. K. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.580271 · Cited by 18
“After highly promising results were obtained in a dog model for Leber’s congenital amaurosis, a disease causing loss of sight [62,63], a real breakthrough was presented in 2008 as several groups presented data showing efficient gene transfer with AAV2-based vectors into the human retinal epithelium and improved vision…”
ResultDawn of ocular gene therapy: implications for molecular diagnosis in retinal disease
Zaneveld, J. E., Wang, F., Wang, X., & Chen, R. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4443-y · Cited by 17
Lung gene therapy—How to capture illumination from the light already present in the tunnel
Xia, E., Munegowda, M. A., Cao, H., & Hu, J. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.001 · Cited by 18
New Method for Efficient siRNA Delivery in Retina Explants: Reverse Magnetofection
Bassetto, M., Sen, M., Poulhès, F., Arango‐González, B., Bonvin, E., Sapet, C., Ueffing, M., & Zelphati, O. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00132 · Cited by 18
A Single Intravenous AAV9 Injection Mediates Bilateral Gene Transfer to the Adult Mouse Retina
Bemelmans, A., Duqué, S. I., Rivière, C., Astord, S., Desrosiers, M., Marais, T., Sahel, J., Voït, T., & Barkats, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061618 · Cited by 22
Gene Therapy in Large Animal Models of Human Genetic Diseases
Wolfe, J. H. N. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.107 · Cited by 17
Genetische und klinische Heterogenität bei LCA-Patienten: Das Ende der Einheitlichkeit
Preising, M. N., Paunescu, K., Friedburg, C., & Lorenz, B. (2007) · Der Ophthalmologe · doi:10.1007/s00347-007-1533-x · Cited by 17
“Diese im Tiermodell bereits sehr erfolgreiche Therapie könnte ohne Kenntnis des ursächlichen Gens nicht stattfinden, da es sich um eine Substitution des funktionslosen Gens handelt [1].”
BackgroundRecent advances in early-onset severe retinal degeneration: more than just basic research?
Preising, M. N., & Heegaard, S. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.12.002 · Cited by 17
Seeing the light: New insights into the molecular pathogenesis of retinal diseases
Campochiaro, P. A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21213 · Cited by 23
The complexities of ocular genetics
Saleem, R., & Walter, M. A. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.610201.x · Cited by 20
“It has also been shown that null mutations of RPGRIP can cause LCA (68).”
MethodInfluentialReloading the retina by modifying the glial matrix
Quinlan, R. A., & Nilsson, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.02.009 · Cited by 17
SuccessfulRPE65Gene Replacement and Improved Visual Function in Humans
Koenekoop, R. K. (2008) · Ophthalmic Genetics · doi:10.1080/13816810802216480 · Cited by 21
Pontikos, N., Woof, W. A., Veturi, Y. A., Javanmardi, B., Ibarra-Arellano, M. A., Hustinx, A., Moghul, I., Liu, Y., Pfau, K., Georgiou, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2110140/v1 · Cited by 18
Animal models for the evaluation of retinal stem cell therapies
Thomas, B. B., Nair, D. S. R., Rahimian, M., Hassan, A. K., Tran, T.-L., & Seiler, M. J. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101356 · Cited by 16
“…(Del Priore et al., 1995; Petters et al., 1997; Ghosh et al., 2004; Klassen et al., 2012; Duarri et al., 2021), dogs (Petersen-Jones et al., 1999; Acland et al., 2001; Zhang et al., 2002; Pichard et al., 2016; Guziewicz et al., 2018; Makelainen et al., 2019; Winkler et al., 2020) and even…”
Nikonov, S. S., Aravand, P., Lyubarsky, A., Nikonov, R., Luo, A. J., Wei, Z., Maguire, A. M., Phelps, N. T., Shpylchak, I., Willett, K. L., et al. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.5.24 · Cited by 16
Self-citationMembrane fouling during ultrafiltration of plasmid DNA through semipermeable membranes
Borujeni, E. E., & Zydney, A. L. (2013) · Journal of Membrane Science · doi:10.1016/j.memsci.2013.08.032 · Cited by 16
Bennett, J., Chung, D. C., & Maguire, A. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00013-2 · Cited by 20
“This allows instruments to be introduced under direct visualization with an anterior approach (Acland et al., 2001, 2005; Amado et al., 2010; Bennicelli et al., 2008).”
MethodSelf-citationLéveillard, T., Fridlich, R., Clérin, E., Aït-Ali, N., Millet-Puel, G., Jaillard, C., Yang, Y., Zack, D. J., DORSSELAER, A. V., & Sahel, J. (2014) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2013.12.002 · Cited by 21
“In 2001, the disease was successfully cured in a dog model of LCA by delivering a normal copy of the gene by an AAV [34].”
BackgroundLandau, K., & Kurz-Levin, M. M. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52903-9.00010-8 · Cited by 20
Absence of Functional and Structural Abnormalities Associated with Expression of EGFP in the Retina
Nour, M., Quiambao, A. B., Al-Ubaidi, M. R., & Naash, M. I. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0663 · Cited by 16
An illuminating new step in visual-pigment regeneration
Pepperberg, D. R., & Crouch, R. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07231-2 · Cited by 18
Moschos, M., Chatziralli, I., Verriopoulos, G., Triglianos, A., Ladas, D. S., & Brouzas, D. (2013) · Clinical ophthalmology · doi:10.2147/opth.s50752 · Cited by 15
“However, novel treatments including gene therapy, 6,7 tissue transplantation, 8,9 or retinal prosthesis 10–13 offer optimism on the subject.”
Modulation of Transgene Expression in Retinal Gene Therapy by Selective Laser Treatment
Lavinsky, D., Chalberg, T. W., Mandel, Y., Huie, P., Dalal, R., Marmor, M. F., & Palanker, D. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10933 · Cited by 16
Lei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_77 · Cited by 16
“While no long ago such conditions were regarded untreatable and incurable by any means, gene therapy has preserved retinal morphology and restored retinal functions in several animal models of retinal degenerations (Ali et al. 2000; Acland et al. 2001; Allocca et al. 2006; Alexander et al. 2007).”
Background
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.